Name: SAG (Smoothened Agonist)
Brand: Selleck Chemicals
SKU: S6384
Rating: 5 (16 reviews)

SAG (Smoothened Agonist) is a potent agonist of Smoothened (Smo). Smoothened Agonist induces firefly luciferase expression in Shh-LIGHT2 cells with an EC50 of 3 nM.

SAG (Smoothened Agonist) Chemical Structure

CAS: 912545-86-9

Selleck's SAG (Smoothened Agonist) has been cited by 16 publications

Purity & Quality Control

Batch: Purity: 99.94%

99.94

SAG (Smoothened Agonist) Related Products

Related Targets	Hedgehog Smoothened GLI	Click to Expand
Related Products	Vismodegib (GDC-0449) Cyclopamine GANT61 SAG (Smoothened Agonist) HCl Sonidegib Purmorphamine Itraconazole SANT-1 BMS-833923 HPI-4 (Ciliobrevin A) Taladegib (LY2940680) PF-5274857 Glasdegib Jervine Ciliobrevin D MK-4101 JK184	Click to Expand
Related Compound Libraries	Kinase Inhibitor Library FDA-approved Drug Library Stem Cell Signaling Compound Library GPCR Compound Library Stem Cell Differentiation Compound Library	Click to Expand

Signaling Pathway

Hedgehog/Smoothened Signaling Pathway

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description

SAG (Smoothened Agonist) is a potent agonist of Smoothened (Smo). Smoothened Agonist induces firefly luciferase expression in Shh-LIGHT2 cells with an EC50 of 3 nM.

Targets

Smo ^[1]
(in Shh-LIGHT2 cells)

3 nM(EC50)

In vitro
In vitro	SAG can counteract glucocorticoids (GCs) antagonism of Shh-driven granule neuron precursor (CGNP) proliferation.^[2]
Cell Research	Cell lines	Granule neuron precursor (CGNP) primary cells
	Concentrations	15-240 nM
	Incubation Time	24 h
	Method	CGNP are stimulated by various SAG concentrations (15 to 240 nM) compared with ShhN (3 μg/ml) and vehicle after 24 hours in vitro. Quantitative reverse transcription–PCR is performed with SYBR Green master mix in LightCycler 480.

In Vivo
In vivo	Systemic administration of Smoothened Agonist (SAG) prevents the neurotoxic effects of glucocorticoids. Smoothened Agonist can cross the blood-brain barrier to activate Shh transcriptional targets in vivo. SAG at the treatment dose effectively prevents GC-induced neonatal cerebellar developmental abnormalities.^[2]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05937178	Recruiting	Hepatitis B Chronic	Huashan Hospital\|The First Affiliated Hospital of Anhui Medical University\|Anhui Provincial Hospital\|Beijing YouAn Hospital\|Peking University People''s Hospital\|Peking University First Hospital\|Xiamen Hospital of Traditional Chinese Medicine\|First Affiliated Hospital of Fujian Medical University\|LanZhou University\|Third Affiliated Hospital Sun Yat-Sen University\|First Affiliated Hospital of Guangxi Medical University\|The Affiliated Hospital Of Guizhou Medical University\|Hainan General Hospital\|Hebei Medical University Third Hospital\|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine\|Henan Provincial People''s Hospital\|The Second Affiliated Hospital of Harbin Medical University\|Tongji Hospital\|Wuhan Union Hospital China\|Renmin Hospital of Wuhan University\|Central South University\|Xiangya Hospital of Central South University\|The First Hospital of Jilin University\|the Second Hospital of Nangjing\|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School\|The First Affiliated Hospital with Nanjing Medical University\|The Affiliated Hospital of Xuzhou Medical University\|The First Affiliated Hospital of Nanchang University\|Shengjing Hospital\|Qingdao Sixth People''s Hospital\|Shandong Provincial Hospital\|The Second Hospital of Shandong University\|The First Affiliated Hospital of Shanxi Medical University\|Tang-Du Hospital\|First Affiliated Hospital Xi''an Jiaotong University\|Ruijin Hospital\|West China Hospital\|Tianjin Second People''s Hospital\|First Affiliated Hospital of Xinjiang Medical University\|The First People''s Hospital of Yunnan\|Shulan (Hangzhou) Hospital\|Zhejiang University\|Southwest Hospital China\|The Second Affiliated Hospital of Chongqing Medical University\|Sichuan Provincial People''s Hospital	January 31 2023	--
NCT05701592	Recruiting	Posterior Cruciate Ligament Tear	Konrad Malinowski MD\|Artromedical Konrad Malinowski Clinic	December 20 2022	--
NCT03645044	Active not recruiting	Hiv\|HBV Coinfection	University of Melbourne\|National Health and Medical Research Council Australia\|The University of Western Australia\|University of Adelaide\|The HIV Netherlands Australia Thailand Research Collaboration\|University of Malaya\|YR Gaitonde Centre for AIDS Research and Education\|Melbourne Health	May 24 2018	--

References

Chemical Information & Solubility

Molecular Weight	490.06	Formula	C₂₈H₂₈ClN₃OS
CAS No.	912545-86-9	SDF	--
Smiles	CNC1CCC(CC1)N(CC2=CC(=CC=C2)C3=CC=NC=C3)C(=O)C4=C(Cl)C5=CC=CC=C5S4
Storage (From the date of receipt)	3 years -20°C powder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years -20°C powder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 98 mg/mL ( (199.97 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 98 mg/mL

Water : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):